Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer, 23735-23737 [2021-09330]

Download as PDF Federal Register / Vol. 86, No. 84 / Tuesday, May 4, 2021 / Notices ‘‘food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.’’ This technology discloses formulation and methods of using novel stealth lipid nanoparticles that have a high stability and payload capacity. Combination of these nanoparticles with selected agents may have various medical applications for cancer and anti-inflammatory indications. This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404. In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available. License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed). Date: May 26, 2021. Time: 10:00 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G41, Rockville, MD 20892 (Virtual Meeting). Contact Person: Tara Capece, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G41, Rockville, MD 20852, 240–191–4281, capecet2@ niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: April 28, 2021. Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2021–09270 Filed 5–3–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Dated: April 16, 2021. Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute. Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer [FR Doc. 2021–09332 Filed 5–3–21; 8:45 am] BILLING CODE 4140–01–P AGENCY: National Institutes of Health, HHS. DEPARTMENT OF HEALTH AND HUMAN SERVICES ACTION: khammond on DSKJM1Z7X2PROD with NOTICES National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 17:13 May 03, 2021 Jkt 253001 The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Athenex, Inc. (‘‘Athenex’’) headquartered in Buffalo, NY. DATES: Only written comments and/or applications for a license which are SUMMARY: National Institutes of Health VerDate Sep<11>2014 Notice. PO 00000 Frm 00066 Fmt 4703 Sfmt 4703 23735 received by the National Cancer Institute’s Technology Transfer Center on or before May 19, 2021 will be considered. Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Suna Gulay French, Ph.D., Technology Transfer Manager, NCI Technology Transfer Center, Telephone: (240) 276–5530; Email: suna.gulay@ nih.gov. ADDRESSES: SUPPLEMENTARY INFORMATION: Intellectual Property Group A E–237–2017–0/2: T Cell Receptors Recognizing Mutated P53 1. US Provisional Patent Application 62/565,383, filed September 29, 2017 (E–237–2017–0–US–01); 2. International Patent Application PCT/US2018/051285, filed September 17, 2018 (E–237–2017–2–PCT–01); 3. Australian Patent Application 2018342246, filed September 17, 2018 (E–237–2017–2–AU–02); 4. Brazilian Patent Application BR112020006012–7, filed September 17, 2018 (E–237–2017–2–BR–03); 5. Canadian Patent Application 3077024, filed September 17, 2018 (E–237–2017–2–CA–04); 6. Chinese Patent Application 201880074539.8, filed September 17, 2018 (E–237–2017–2–CN–05); 7. Costa Rica Patent Application 2020–0170, filed September 17, 2018 (E–237–2017–2–CR–06); 8. Eurasian Patent Application 202090757, filed September 17, 2018 (E–237–2017–2–EA–07); 9. European Patent Application 18780006.5, filed September 17, 2018 (E–237–2017–2–EP–08); 10. Israeli Patent Application 273515, filed September 17, 2018 (E–237–2017– 2–IL–09); 11. India Patent Application 202047013911, filed September 17, 2018 (E–237–2017–2–IN–10); 12. Japanese Patent Application 2020– 517556, filed September 17, 2018 (E–237–2017–2–JP–11); 13. Korean Patent Application 2020– 7012344, filed September 17, 2018 (E–237–2017–2–KR–12); 14. Mexico Patent Application MX/a/ 2020/003504, filed September 17, 2018 (E–237–2017–2–MX–13); 15. New Zealand Patent Application 763023, filed September 17, 2018 (E–237–2017–2–NZ–14); 16. Singapore Patent Application 11202002636P, filed September 17, 2018 (E–237–2017–2–SG–15); E:\FR\FM\04MYN1.SGM 04MYN1 23736 Federal Register / Vol. 86, No. 84 / Tuesday, May 4, 2021 / Notices E–190–2020: HLA Class I-Restricted T Cell Receptors Against RAS With G12V Mutation 17. United States Utility Patent Application 16/651,242, filed September 17, 2018 (E–237–2017–2– US–16); and 18. Hong Kong Patent Application 62020021272.3, filed November 30, 2020 (E–237–2017–2–HK–17). 1. US Provisional Application 63/ 060,340, filed August 3, 2020 (E–190– 2020–0–US–01). E–135–2019: T Cell Receptors Recognizing R175H or Y220C Mutation in P53 1. US Provisional Patent Application 62/867,619, filed June 27, 2019 (E–135–2019–0–US–01); 2. International Patent Application PCT/US2020/039785, filed June 26, 2020 (E–135–2019–0–PCT–02); and 3. Taiwanese Patent Application 109121744, filed June 26, 2020 (E–135– 2019–0–TW–03). E–173–2020: T Cell Receptors Recognizing R273C or Y220C Mutation in P53 1. US Provisional Patent Application 63/074,747, filed September 4, 2020 (E– 173–2020–0–US–01). E–098–2018: T Cell Receptors Which Recognize Mutated EGFR 1. US Provisional Patent Application 62/665,234, filed May 1, 2018 (E–098– 2018–0–US–01); 2. International Patent Application PCT/US2019/030108, filed May 1, 2019 (E–098–2018–0–PCT–02); 3. Australian Patent Application 2019263233, filed May 1, 2019 (E–098– 2018–0–AU–03); 4. Canadian Patent Application 3,099,106, filed May 1, 2019 (E–098– 2018–0–CA–04); 5. European Patent Application 19723615.1, filed May 1, 2019 (E–098– 2018–0–EP–05); and 6. United States Utility Patent Application 17/051,860, filed May 1, 2019 (E–098–2018–0–US–06). E–165–2020: HLA Class II-Restricted DRB T Cell Receptors Against RAS With G12D Mutation 1. US Provisional Application 63/ 050,931, filed July 13, 2020 (E–165– 2020–0–US–01). khammond on DSKJM1Z7X2PROD with NOTICES E–172–2020: HLA Class II-Restricted DRB T Cell Receptors Against RAS With G12V Mutation 1. US Provisional Application 63/ 052,502, filed July 16, 2020 (E–172– 2020–0–US–01). E–189–2020: HLA Class II-Restricted DQ T Cell Receptors Against RAS With G13D Mutation 1. US Provisional Application 63/ 086,674, filed October 2, 2020 (E–189– 2020–0–US–01). VerDate Sep<11>2014 17:13 May 03, 2021 Jkt 253001 Group B E–237–2017–1: Methods of Isolating T Cells Having Antigenic Specificity for a P53 Cancer-Specific Mutation 1. US Provisional Patent Application 62/565,464, filed September 29, 2017 (E–237–2017–1–US–01); 2. International Patent Application PCT/US2018/051280, filed September 17, 2018 (E–237–2017–1–PCT–02); 3. Australian Patent Application 2018342245, filed September 17, 2018 (E–237–2017–1–AU–03); 4. Canadian Patent Application 3080274, filed September 17, 2018 (E–237–2017–1–CA–04); 5. Chinese Patent Application 201880063656.4, filed September 17, 2018 (E–237–2017–1–CN–05); 6. European Patent Application 18782605.2, filed September 17, 2018 (E–237–2017–1–EP–06); 7. Israeli Patent Application 273516, filed September 17, 2018 (E–237–2017– 1–IL–07); 8. Japanese Patent Application 2020– 517553, filed September 17, 2018 (E– 237–2017–1–JP–08); 9. Korean Patent Application 2020– 7012343, filed September 17, 2018 (E–237–2017–1–KR–09); 10. Singapore Patent Application 11202002635R, filed September 17, 2018 (E–237–2017–1–SG–10); 11. United States Utility Patent Application 16/650,696, filed September 17, 2018 (E–237–2017–1– US–11); and 12. Hong Kong Patent Application 62020021274.9, filed November 30, 2020 (E–237–2017–1–HK–12). The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America. The prospective exclusive license territory may be worldwide and the field of use may be limited to the following: Fields of Use Applying to Intellectual Property Group A ‘‘Development, manufacture and commercialization of autologous, peripheral blood T cell therapy products engineered via retrovirus and lentivirusmediated gene transfer to express T cell receptors reactive to mutated p53, KRAS and EGFR within the context of multiple HLAs, as claimed in the Licensed Patent Rights, for the treatment PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 of human cancers. Specifically excluded from this field of use are, (a) transposonengineered peripheral blood T cell therapy products for the treatment of human cancers, and (b) CRISPRengineered peripheral blood T cell therapy products for the treatment of human cancers. Development, manufacture, and commercialization of companion diagnostics approved or cleared by the FDA or equivalent foreign regulatory agency for Licensee-proprietary T cell therapy products.’’ Fields of Use Applying to Intellectual Property Group B ‘‘Development, manufacture and commercialization of autologous, peripheral blood T cell therapy products engineered via retrovirus and lentivirusmediated gene transfer to express T cell receptors reactive to mutated P53, isolated as claimed in the Licensed Patent Rights, for the treatment of human cancers. Specifically excluded from this field of use are, (a) transposonengineered peripheral blood T cell therapy products for the treatment of human cancers, and (b) CRISPRengineered peripheral blood T cell therapy products for the treatment of human cancers. Development, manufacture, and commercialization of companion diagnostics approved or cleared by the FDA or equivalent foreign regulatory agency for Licensee-proprietary T cell therapy products.’’ Intellectual Property Group A description is as follows: E–237–2017–0, E–135–2019 and E– 173–2020 patent rights are primarily directed to isolated TCRs reactive to mutated tumor protein 53 (TP53 or P53), within the context of several HLAs. P53 is the archetypal tumor suppressor gene and the most frequently mutated gene in cancer. Contemporary estimates suggest that >50% of all tumors carry mutations in P53. Because of its prevalence in cancer and its restricted expression to precancerous and cancerous cells, this antigen may be targeted on mutant P53expressing tumors with minimal normal tissue toxicity. E–165–2020, E–172–2020, E–189– 2020 and E–190–2020 patent rights are primarily directed to isolated TCRs reactive to mutated Kirsten rat sarcoma viral oncogene homolog (KRAS), within the context of several human leukocyte antigens (HLAs). Mutated KRAS, which plays a well-defined driver role in oncogenesis, is expressed by a variety of human cancers, including: Pancreatic, lung, endometrial, ovarian and prostate. Due to its restricted expression in precancerous and cancerous cells, this E:\FR\FM\04MYN1.SGM 04MYN1 khammond on DSKJM1Z7X2PROD with NOTICES Federal Register / Vol. 86, No. 84 / Tuesday, May 4, 2021 / Notices antigen may be targeted on mutant KRAS-expressing tumors with minimal normal tissue toxicity. E–098–2018 patent rights are primarily directed to isolated TCRs reactive to mutated epidermal growth factor receptor (EGFR), within the context of HLA DPA1*02:01 DPB1*01:01. EGFR is a transmembrane protein involved in cell growth and proliferation signaling. Mutations in the gene encoding EGFR can lead to its overexpression, causing several types of cancer (e.g., non-small cell lung cancer (NSCLC)). Because of its prevalence in certain cancers and its restricted expression to precancerous and cancerous tissues, this antigen may be targeted on mutant EGFR-expressing tumors with minimal normal tissue toxicity. Intellectual Property Group B description is as follows: E–237–2017–1 patent rights are primarily directed to methods of rapidly isolating T cells which are reactive to mutated P53 antigens. Briefly, pools of 25-mer peptides covering all known P53 ‘‘hotspot’’ mutations have been generated. These peptides may be pulsed into autologous antigen presenting cells which are subsequently co-cultured with the patient’s isolated T cells. Reactive T cells are then purified and may be used as source material for the further isolation of mutant P53targeting TCRs. This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available. License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552. VerDate Sep<11>2014 17:13 May 03, 2021 Jkt 253001 Dated: April 21, 2021. Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute. [FR Doc. 2021–09330 Filed 5–3–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF THE INTERIOR Bureau of Land Management [L14400000 PN0000 HQ350000 212; OMB Control Number 1004–0012] Agency information collection activities; Application for Land for Recreation or Public Purposes Bureau of Land Management, Interior. ACTION: Notice of information collection; request for comment. AGENCY: In accordance with the Paperwork Reduction Act of 1995, the Bureau of Land Management (BLM) proposes to renew an information collection. SUMMARY: Interested persons are invited to submit comments on or before July 6, 2021. DATES: Send your written comments on this information collection request (ICR) by mail to Darrin King, Information Collection Clearance Officer, U.S. Department of the Interior, Bureau of Land Management, Attention PRA Office, 440 W 200 S #500, Salt Lake City, UT 84101; or by email to BLM_HQ_PRA_ Comments@blm.gov. Please reference Office of Management and Budget (OMB) Control Number 1004–0012 in the subject line of your comments. Please note that due to COVID–19, the electronic submission of comments is recommended. ADDRESSES: To request additional information about this ICR, contact Susie Greenhalgh by email at lgreenhalgh@blm.gov, or by telephone at 202–302–4288. Individuals who are hearing or speech impaired may call the Federal Relay Service at 1– 800–877–8339 for TTY assistance. You may also view the ICR at https:// www.reginfo.gov/public/do/PRAMain. SUPPLEMENTARY INFORMATION: In accordance with the Paperwork Reduction Act of 1995 (PRA, 44 U.S.C. 3501 et seq.) and 5 CFR 1320.8(d)(1), all information collections require approval under the PRA. The BLM may not conduct, or sponsor, and you are not required to respond to, a collection of information unless it displays a currently valid OMB control number. FOR FURTHER INFORMATION CONTACT: PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 23737 As part of our continuing effort to reduce paperwork and respondent burdens, we invite the public and other Federal agencies to comment on new, proposed, revised, and continuing collections of information. This helps us assess the impact of our information collection requirements and minimize the public’s reporting burden. It also helps the public understand our information collection requirements and provide the requested data in the desired format. We are especially interested in public comments addressing the following: (1) Whether or not the collection of information is necessary for the proper performance of the functions of the agency, including whether or not the information will have practical utility; (2) The accuracy of our estimate of the burden for this collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) How might the agency minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of response. Comments that you submit in response to this notice are a matter of public record. We will include or summarize each comment in our request to OMB to approve this ICR. Before including your address, phone number, email address, or other personal identifying information in your comment, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so. Abstract: The BLM uses the information collection to decide whether or not to lease or sell certain public lands to applicants under the Recreation and Public Purposes Act, 43 U.S.C. 869 to 869–4. Title of Collection: Application for Land for Recreation or Public Purposes (43 CFR 2740 and 2912). OMB Control Number: 1004–0012. Form Number: 2740–01. Type of Review: Extension of a currently approved collection. Respondents/Affected Public: State, Territory, County, and Local E:\FR\FM\04MYN1.SGM 04MYN1

Agencies

[Federal Register Volume 86, Number 84 (Tuesday, May 4, 2021)]
[Notices]
[Pages 23735-23737]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-09330]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: Development and 
Commercialization of Cell Therapies for Cancer

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, an institute of the National 
Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an Exclusive Patent License to practice the 
inventions embodied in the Patents and Patent Applications listed in 
the Supplementary Information section of this notice to Athenex, Inc. 
(``Athenex'') headquartered in Buffalo, NY.

DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute's Technology Transfer 
Center on or before May 19, 2021 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated an Exclusive Patent License 
should be directed to: Suna Gulay French, Ph.D., Technology Transfer 
Manager, NCI Technology Transfer Center, Telephone: (240) 276-5530; 
Email: [email protected].

SUPPLEMENTARY INFORMATION: 

Intellectual Property

Group A

E-237-2017-0/2: T Cell Receptors Recognizing Mutated P53

    1. US Provisional Patent Application 62/565,383, filed September 
29, 2017 (E-237-2017-0-US-01);
    2. International Patent Application PCT/US2018/051285, filed 
September 17, 2018 (E-237-2017-2-PCT-01);
    3. Australian Patent Application 2018342246, filed September 17, 
2018 (E-237-2017-2-AU-02);
    4. Brazilian Patent Application BR112020006012-7, filed September 
17, 2018 (E-237-2017-2-BR-03);
    5. Canadian Patent Application 3077024, filed September 17, 2018 
(E-237-2017-2-CA-04);
    6. Chinese Patent Application 201880074539.8, filed September 17, 
2018 (E-237-2017-2-CN-05);
    7. Costa Rica Patent Application 2020-0170, filed September 17, 
2018 (E-237-2017-2-CR-06);
    8. Eurasian Patent Application 202090757, filed September 17, 2018 
(E-237-2017-2-EA-07);
    9. European Patent Application 18780006.5, filed September 17, 2018 
(E-237-2017-2-EP-08);
    10. Israeli Patent Application 273515, filed September 17, 2018 (E-
237-2017-2-IL-09);
    11. India Patent Application 202047013911, filed September 17, 2018 
(E-237-2017-2-IN-10);
    12. Japanese Patent Application 2020-517556, filed September 17, 
2018 (E-237-2017-2-JP-11);
    13. Korean Patent Application 2020-7012344, filed September 17, 
2018 (E-237-2017-2-KR-12);
    14. Mexico Patent Application MX/a/2020/003504, filed September 17, 
2018 (E-237-2017-2-MX-13);
    15. New Zealand Patent Application 763023, filed September 17, 2018 
(E-237-2017-2-NZ-14);
    16. Singapore Patent Application 11202002636P, filed September 17, 
2018 (E-237-2017-2-SG-15);

[[Page 23736]]

    17. United States Utility Patent Application 16/651,242, filed 
September 17, 2018 (E-237-2017-2-US-16); and
    18. Hong Kong Patent Application 62020021272.3, filed November 30, 
2020 (E-237-2017-2-HK-17).

E-135-2019: T Cell Receptors Recognizing R175H or Y220C Mutation in P53

    1. US Provisional Patent Application 62/867,619, filed June 27, 
2019 (E-135-2019-0-US-01);
    2. International Patent Application PCT/US2020/039785, filed June 
26, 2020 (E-135-2019-0-PCT-02); and
    3. Taiwanese Patent Application 109121744, filed June 26, 2020 (E-
135-2019-0-TW-03).

E-173-2020: T Cell Receptors Recognizing R273C or Y220C Mutation in P53

    1. US Provisional Patent Application 63/074,747, filed September 4, 
2020 (E-173-2020-0-US-01).

E-098-2018: T Cell Receptors Which Recognize Mutated EGFR

    1. US Provisional Patent Application 62/665,234, filed May 1, 2018 
(E-098-2018-0-US-01);
    2. International Patent Application PCT/US2019/030108, filed May 1, 
2019 (E-098-2018-0-PCT-02);
    3. Australian Patent Application 2019263233, filed May 1, 2019 (E-
098-2018-0-AU-03);
    4. Canadian Patent Application 3,099,106, filed May 1, 2019 (E-098-
2018-0-CA-04);
    5. European Patent Application 19723615.1, filed May 1, 2019 (E-
098-2018-0-EP-05); and
    6. United States Utility Patent Application 17/051,860, filed May 
1, 2019 (E-098-2018-0-US-06).

E-165-2020: HLA Class II-Restricted DRB T Cell Receptors Against RAS 
With G12D Mutation

    1. US Provisional Application 63/050,931, filed July 13, 2020 (E-
165-2020-0-US-01).

E-172-2020: HLA Class II-Restricted DRB T Cell Receptors Against RAS 
With G12V Mutation

    1. US Provisional Application 63/052,502, filed July 16, 2020 (E-
172-2020-0-US-01).

E-189-2020: HLA Class II-Restricted DQ T Cell Receptors Against RAS 
With G13D Mutation

    1. US Provisional Application 63/086,674, filed October 2, 2020 (E-
189-2020-0-US-01).

E-190-2020: HLA Class I-Restricted T Cell Receptors Against RAS With 
G12V Mutation

    1. US Provisional Application 63/060,340, filed August 3, 2020 (E-
190-2020-0-US-01).

Group B

E-237-2017-1: Methods of Isolating T Cells Having Antigenic Specificity 
for a P53 Cancer-Specific Mutation

    1. US Provisional Patent Application 62/565,464, filed September 
29, 2017 (E-237-2017-1-US-01);
    2. International Patent Application PCT/US2018/051280, filed 
September 17, 2018 (E-237-2017-1-PCT-02);
    3. Australian Patent Application 2018342245, filed September 17, 
2018 (E-237-2017-1-AU-03);
    4. Canadian Patent Application 3080274, filed September 17, 2018 
(E-237-2017-1-CA-04);
    5. Chinese Patent Application 201880063656.4, filed September 17, 
2018 (E-237-2017-1-CN-05);
    6. European Patent Application 18782605.2, filed September 17, 2018 
(E-237-2017-1-EP-06);
    7. Israeli Patent Application 273516, filed September 17, 2018 (E-
237-2017-1-IL-07);
    8. Japanese Patent Application 2020-517553, filed September 17, 
2018 (E-237-2017-1-JP-08);
    9. Korean Patent Application 2020-7012343, filed September 17, 2018 
(E-237-2017-1-KR-09);
    10. Singapore Patent Application 11202002635R, filed September 17, 
2018 (E-237-2017-1-SG-10);
    11. United States Utility Patent Application 16/650,696, filed 
September 17, 2018 (E-237-2017-1-US-11); and
    12. Hong Kong Patent Application 62020021274.9, filed November 30, 
2020 (E-237-2017-1-HK-12).
    The patent rights in these inventions have been assigned and/or 
exclusively licensed to the government of the United States of America.
    The prospective exclusive license territory may be worldwide and 
the field of use may be limited to the following:
Fields of Use Applying to Intellectual Property Group A
    ``Development, manufacture and commercialization of autologous, 
peripheral blood T cell therapy products engineered via retrovirus and 
lentivirus-mediated gene transfer to express T cell receptors reactive 
to mutated p53, KRAS and EGFR within the context of multiple HLAs, as 
claimed in the Licensed Patent Rights, for the treatment of human 
cancers. Specifically excluded from this field of use are, (a) 
transposon-engineered peripheral blood T cell therapy products for the 
treatment of human cancers, and (b) CRISPR-engineered peripheral blood 
T cell therapy products for the treatment of human cancers.
    Development, manufacture, and commercialization of companion 
diagnostics approved or cleared by the FDA or equivalent foreign 
regulatory agency for Licensee-proprietary T cell therapy products.''
Fields of Use Applying to Intellectual Property Group B
    ``Development, manufacture and commercialization of autologous, 
peripheral blood T cell therapy products engineered via retrovirus and 
lentivirus-mediated gene transfer to express T cell receptors reactive 
to mutated P53, isolated as claimed in the Licensed Patent Rights, for 
the treatment of human cancers. Specifically excluded from this field 
of use are, (a) transposon-engineered peripheral blood T cell therapy 
products for the treatment of human cancers, and (b) CRISPR-engineered 
peripheral blood T cell therapy products for the treatment of human 
cancers.
    Development, manufacture, and commercialization of companion 
diagnostics approved or cleared by the FDA or equivalent foreign 
regulatory agency for Licensee-proprietary T cell therapy products.''
    Intellectual Property Group A description is as follows:
    E-237-2017-0, E-135-2019 and E-173-2020 patent rights are primarily 
directed to isolated TCRs reactive to mutated tumor protein 53 (TP53 or 
P53), within the context of several HLAs. P53 is the archetypal tumor 
suppressor gene and the most frequently mutated gene in cancer. 
Contemporary estimates suggest that >50% of all tumors carry mutations 
in P53. Because of its prevalence in cancer and its restricted 
expression to precancerous and cancerous cells, this antigen may be 
targeted on mutant P53-expressing tumors with minimal normal tissue 
toxicity.
    E-165-2020, E-172-2020, E-189-2020 and E-190-2020 patent rights are 
primarily directed to isolated TCRs reactive to mutated Kirsten rat 
sarcoma viral oncogene homolog (KRAS), within the context of several 
human leukocyte antigens (HLAs). Mutated KRAS, which plays a well-
defined driver role in oncogenesis, is expressed by a variety of human 
cancers, including: Pancreatic, lung, endometrial, ovarian and 
prostate. Due to its restricted expression in precancerous and 
cancerous cells, this

[[Page 23737]]

antigen may be targeted on mutant KRAS-expressing tumors with minimal 
normal tissue toxicity.
    E-098-2018 patent rights are primarily directed to isolated TCRs 
reactive to mutated epidermal growth factor receptor (EGFR), within the 
context of HLA DPA1*02:01 DPB1*01:01. EGFR is a transmembrane protein 
involved in cell growth and proliferation signaling. Mutations in the 
gene encoding EGFR can lead to its overexpression, causing several 
types of cancer (e.g., non-small cell lung cancer (NSCLC)). Because of 
its prevalence in certain cancers and its restricted expression to 
precancerous and cancerous tissues, this antigen may be targeted on 
mutant EGFR-expressing tumors with minimal normal tissue toxicity.
    Intellectual Property Group B description is as follows:
    E-237-2017-1 patent rights are primarily directed to methods of 
rapidly isolating T cells which are reactive to mutated P53 antigens. 
Briefly, pools of 25-mer peptides covering all known P53 ``hotspot'' 
mutations have been generated. These peptides may be pulsed into 
autologous antigen presenting cells which are subsequently co-cultured 
with the patient's isolated T cells. Reactive T cells are then purified 
and may be used as source material for the further isolation of mutant 
P53-targeting TCRs.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the National 
Cancer Institute receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially, and may be 
made publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information in these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: April 21, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2021-09330 Filed 5-3-21; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.